Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Charter Communications, Inc. due to alleged violations of federal securities laws, particularly related to misleading statements about the company's performance and the impact of the Affordable Connectivity Program (ACP) ending [1][3]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Charter between July 26, 2024, and July 24, 2025, to discuss their legal options [1]. - The firm has set an October 13, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Charter [1]. Allegations Against Charter - The complaint alleges that Charter and its executives made false or misleading statements and failed to disclose significant impacts from the end of the ACP, which affected internet customer declines and revenue [3]. - Specific claims include that Charter was unable to manage the impact of the ACP ending, leading to greater risks on business plans and earnings growth than reported [3]. Financial Performance - On July 25, 2025, Charter reported a decline of 117,000 internet customers in Q2 2025, compared to a decline of about 100,000 in Q2 2024, after adjusting for the ACP's impact [4]. - The company's total video customers also decreased by 80,000, resulting in a stock price drop of $70.25 per share, or 18.5%, closing at $309.75 on the same day [4]. Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is typical of class members and oversees the litigation [5]. - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Contact Information - For more information regarding the class action against Charter, interested parties can visit the Faruqi & Faruqi website or contact partner Josh Wilson directly [6].

Core Viewpoint - A class action lawsuit has been filed against Snap, Inc. for allegedly providing misleading statements regarding its advertising revenue growth, leading to significant losses for investors who purchased shares between April 29, 2025, and August 5, 2025 [7]. Allegation Details - The lawsuit claims that Snap's management made overly positive statements about the company's performance while concealing material adverse facts about its advertising revenue growth rate, which dropped from 9% in Q1 to only 1% in April 2025 [7]. - Snap's financial results announced on August 5, 2025, revealed a deceleration in advertising revenue growth, attributed to issues with its ad platform and external factors like the timing of Ramadan [7]. Stock Price Impact - Following the announcement of disappointing financial results, Snap's stock price fell from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in just one day [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug efzofitimod, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1][4]. - A federal securities class action has been filed against aTyr, with a deadline of December 9, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [6]. - The EFZO-FIT study results indicated that efzofitimod did not show a significant reduction in mean daily oral corticosteroid (OCS) dose compared to placebo, with only 52.6% of patients achieving complete steroid withdrawal [7]. Group 3: Stock Performance Impact - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].

Core Viewpoint - A class action lawsuit has been filed against WPP plc, alleging that the company misled investors about its media arm's performance and ability to handle macroeconomic challenges, leading to significant stock price declines [4][5][6]. Company Summary - WPP plc is facing a class action lawsuit initiated by Jack Marty, which claims that the company provided misleading positive statements while concealing adverse facts about its media operations [4]. - The lawsuit covers the period from February 27, 2025, to July 8, 2025, during which WPP's stock price fell dramatically after the company reported a deterioration in performance [5][6]. - On July 9, 2025, WPP disclosed that it had experienced a decline in performance due to macroeconomic uncertainties and weaker new business, which was partly attributed to ongoing restructuring efforts [5]. Stock Performance - Following the negative trading update on July 9, 2025, WPP's stock price dropped from $35.82 to $29.34 per share, representing an approximate decline of 18.1% in one day [6].

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, Incorporated for failing to disclose material information during the class period from December 27, 2023, to May 6, 2025, which is in violation of federal securities laws [1][3]. Summary by Sections Lawsuit Details - Investors have until November 17, 2025, to file lead plaintiff applications in the lawsuit against Cytokinetics [1]. - The lawsuit is pending in the United States District Court for the Northern District of California [1]. Company Disclosures - On March 10, 2025, Cytokinetics announced that the FDA would not hold an advisory committee meeting to review its New Drug Application for the aficamten product [4]. - On May 6, 2025, the company revealed it had multiple pre-NDA meetings with the FDA regarding safety monitoring and risk mitigation but opted to submit the NDA without a Risk Evaluation and Mitigation Strategy [4]. Stock Price Impact - Following the disclosures, Cytokinetics' share price fell to $33.04 per share on May 7, 2025 [5]. Law Firm Background - Kahn Swick & Foti, LLC is a prominent securities litigation law firm, ranked among the top 10 firms nationally based on total settlement value [5]. - The firm represents a variety of clients, including institutional and retail investors, seeking recoveries for investment losses due to corporate fraud [5].

Core Viewpoint - A securities class action lawsuit has been filed against Dow Inc. for failing to disclose material information during the class period, which has led to significant financial losses for investors [3]. Group 1: Lawsuit Details - Investors who purchased Dow securities between January 30, 2025, and July 23, 2025, have until October 28, 2025, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Eastern District of Michigan, under the case name Sarti v. Dow Inc., No. 25-cv-12744 [5]. Group 2: Financial Performance - On July 24, 2025, Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly higher than the expected loss of approximately $0.17 to $0.18 per share [4]. - The company's net sales for the same quarter were $10.1 billion, reflecting a 7.3% year-over-year decline and missing consensus estimates by $130 million [4]. - Dow announced a dividend cut from $0.70 per share to $0.35 per share, citing the need for financial flexibility in a challenging macroeconomic environment [4]. Group 3: Market Reaction - Following the financial disclosures, Dow's share price fell by $5.30, or 17.45%, closing at $25.07 per share on July 24, 2025 [4].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nutex (NUTX) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nutex between August 8, 2024 and August 14, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar ...

Core Insights - Short-seller reports can significantly disrupt a public company's trajectory by alleging financial misstatements or improper practices, often leading to a decline in stock prices for the benefit of the short-sellers [1][2] - The legal landscape surrounding short-seller reports is evolving, with courts increasingly allowing these reports to be used in securities litigation, which poses challenges for corporate leaders [2][3] Impact on Companies - The publication of short-seller reports can lead to immediate market volatility, eroding shareholder value and destabilizing investor relations [6] - Companies face multi-dimensional threats from short-seller reports, including potential litigation and reputational damage [4][6] Legal Considerations - Courts assess whether short-seller reports reveal genuinely new and credible information or merely compile existing data, impacting their admissibility in legal claims [3][5] - Recent court decisions indicate that while skepticism exists regarding short-seller reports, they can still be used to support claims of loss causation in securities litigation [5] Recommended Actions for Companies - Companies should annotate short reports under attorney direction to preserve legal protections and guide internal responses [7] - Public responses to short-seller reports should be carefully evaluated to avoid backlash, and offensive strategies may be employed selectively [8] - Monitoring stock price movements and trading activity is crucial, as courts often consider market reactions as evidence of loss causation [9][10] - Tracking short interest and derivatives activity can help identify coordinated short-selling campaigns [11] - Engaging specialized legal counsel with expertise in short-seller defense early in the process is essential for effective response [12] - Boards of directors should be promptly informed and involved in oversight to protect the company's interests [17] - Proactive communication with long-term investors and sell-side analysts can help mitigate reputational harm and counteract short-seller narratives [18] Conclusion - The prevalence of short-seller reports is expected to continue, and companies that implement strategic responses will be better positioned to maintain their trajectory and protect shareholder interests [19]

Core Viewpoint - A securities class action lawsuit has been filed against Fortinet, Inc. due to allegations of misleading statements regarding its product refresh cycle and growth projections [1][6]. Allegations - The lawsuit claims that Fortinet's statements about entering a major firewall "refresh cycle" were false and misleading, as the refresh involved old products that represented only a small part of the business [6]. - Fortinet projected $400 million to $450 million in product revenue for 2025-2026, but the lawsuit argues that the company lacked clarity on the number of firewalls that could actually be upgraded [6]. - By the second quarter of 2025, Fortinet had already completed nearly half of the refresh, contradicting claims of future momentum [6]. Stock Impact - Following the revelation on August 6, 2025, that Fortinet was 40-50% through the 2026 upgrade cycle and that customers had excess firewall capacity, the company's stock fell by 22%, from $96.58 to $75.30 on August 7, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Snap, Inc. for allegedly providing misleading statements regarding its advertising revenue growth, leading to significant losses for investors during the specified class period [8]. Allegation Details - The lawsuit claims that Snap's management made overly positive statements about the company's performance while concealing material adverse facts about its advertising revenue growth rate, which dropped from 9% in Q1 to only 1% in April [8]. - Snap's financial results announced on August 5, 2025, revealed a deceleration in advertising revenue growth, attributed to issues with its ad platform and other factors [8]. Stock Price Impact - Following the announcement of disappointing financial results, Snap's stock price fell from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [8]. Next Steps for Investors - Investors who purchased Snap shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].